Australia’s biotech sector weighs opportunity amid Trump disruption
Tariffs, FDA cuts and NIH turmoil are reshaping global pharma. Australia’s life sciences sector sees risk — but also a rare chance to gain ground.
The global biomedical industry is being shaken by three disruptive policy shifts from the Trump administration, each with direct implications for Australia’s $5 billion pharmaceutical export sector.
Steep new US tariffs on pharmaceutical imports, sweeping cuts at the Food and Drug Administration (FDA), and a dramatic reduction in National Institutes of Health funding are creating fresh challenges for biotech globally — and surprising opportunities for Australia.
Industry leaders say the Australian government’s response will determine whether the country can seize the moment. Targeted investments in research infrastructure, streamlined visa processes for international scientific talent, and smart trade negotiations could put Australia in a position to thrive amid the upheaval.
“We’re witnessing a fundamental realignment of the global life sciences ecosystem,” said Daniel Getts, an Australian CEO of US-based Myeloid Therapeutics.
